Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

Provided By PR Newswire

Last update: Jun 8, 2022

SBT-272 improved neuronal health, superior to other approved and investigational agents

Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway